2. Lipids
  3. Saccharolipids

Saccharolipids

Saccharolipids (8):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-112174
    UDP-GlcNAc disodium 91183-98-1 99.92%
    UDP-GlcNAc Disodium Salt (UDP-α-D-N-Acetylglucosamine Disodium Salt) is a donor substrate of O-GlcNAc transferase (OGT).
    UDP-GlcNAc disodium
  • HY-N8515C
    UDP-3-O-acyl-GlcNAc disodium
    UDP-3-O-acyl-GlcNAc (UDP-3-O-(3-hydroxytetradecanoyl)-N-acetylglucosamine) disodium is an E. coli metabolite that is involved in 3-deoxy-D-manno-octulosonate (KDO) biosynthesis pathway.
    UDP-3-O-acyl-GlcNAc disodium
  • HY-W585865
    UDP-3-O-acyl-GlcNAc Tris 112710-84-6
    UDP-3-O-acyl-GlcNAc (UDP-3-O-(3-hydroxytetradecanoyl)-N-acetylglucosamine) Tris is an E. coli metabolite that is involved in 3-deoxy-D-manno-octulosonate (KDO) biosynthesis pathway.
    UDP-3-O-acyl-GlcNAc Tris
  • HY-N8515
    UDP-3-O-acyl-GlcNAc 108636-29-9
    UDP-3-O-acyl-GlcNAc (UDP-3-O-(3-hydroxytetradecanoyl)-N-acetylglucosamine) is an E. coli metabolite that is involved in 3-deoxy-D-manno-octulosonate (KDO) biosynthesis pathway.
    UDP-3-O-acyl-GlcNAc
  • HY-N8515B
    UDP-3-O-acyl-GlcNAc diammonium
    UDP-3-O-acyl-GlcNAc diammonium is an E. coli metabolite that is involved in 3-deoxy-D-manno-octulosonate (KDO) biosynthesis pathway.
    UDP-3-O-acyl-GlcNAc diammonium
  • HY-W127355
    Kdo2-Lipid A 123621-04-5
    Kdo2-Lipid A is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    Kdo2-Lipid A
  • HY-148596
    UDP-GlcNAc 528-04-1
    UDP-GlcNAc (UDP-N-Acetyl-D-glucosamine) is an important component and precursor of bacterial peptidoglycan. UDP-GlcNAc also acts as a full agonist of the P2Y14 receptor and inhibits the formation of cAMP. UDP-GlcNAc can be used in studies related to bacterial infections.
    UDP-GlcNAc
  • HY-130581
    Lipid X 86559-73-1
    Lipid X is a 2,3-diacylglucosamine-1-phosphate that serves as the monosaccharide precursor of lipid A, possessing both LPS antagonist and weak agonist activities. Lipid X exerts protective effects by inhibiting tumor necrosis factor production, monocyte procoagulant activity, and neutrophil priming. Lipid X may induce transient pulmonary hypertension, neutropenia, and mild pyrogenic effects in laboratory animals. Lipid X has low toxicity and no in vitro antibacterial activity, but it significantly reduces mortality following Gram-negative bacterial infection and endotoxin exposure. Lipid X tends to accumulate in liver tissue, binds to circulating cellular components, and can be converted to lipid Y through transesterification. Lipid X can be used in research on Gram-negative bacterial sepsis, endotoxemia, and associated pulmonary hypertension.
    Lipid X